Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: A pilot phase II trial of Hypofractionated Intensity-modulated Radiotherapy (H-IMRT) combined with Temozolomide and Bavacizumab in patients with newly diagnosed GBM

 


A pilot phase II trial of Hypofractionated Intensity-modulated Radiotherapy (H-IMRT) combined with Temozolomide and Bavacizumab in patients with newly diagnosed GBM


Trial Focus

Trial Focus

Brain & Nervous System

Objective

        
Eligibility criteria include but are not limited to: 18 years
of age or older with newly diagnosed GBM (Glioblastoma Multiforme).
A screening period will occur to determine study eligibility. The total active treatment period is 6 months.

IRB Protocol #

10-0274

Trial Status

In Progress

Contact

Monica Robischon at 720-848-0661 or monica.robischon@ucdenver.edu

Eligibility and Other Participant Information


Eligibility criteria include but are not limited to: 18 years
of age or older with newly diagnosed GBM (Glioblastoma Multiforme).